会員登録
ログイン
【4594】ブライトパス・バイオ
創薬ベンチャー。がんペプチドワクチンなどを開発。
業績予想修正履歴
| 決算期 | 日付 | 予・実 | 売上高 (百万円) |
対前回 | 修正率 | 修正率 | 営業利益 (百万円) |
対前回 | 修正率 | 修正率 | 経常利益 (百万円) |
対前回 | 修正率 | 修正率 | 当期利益 (百万円) |
対前回 | 修正率 | 修正率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024.03 | 2024/02/09 | Q3予 | 0 | → | - | - | -1,588 | ↓ | -17.4% | -17.4% | -1,589 | ↓ | -17.4% | -17.4% | -1,592 | ↓ | -17.3% | -17.3% |
| 2024.03 | 2023/11/10 | Q2予 | - | - | - | - | -1,353 | → | 0.0% | 0.0% | -1,353 | → | 0.0% | 0.0% | -1,357 | → | 0.0% | 0.0% |
| 2024.03 | 2023/08/10 | Q1予 | 0 | → | - | - | -1,353 | → | 0.0% | 0.0% | -1,353 | → | 0.0% | 0.0% | -1,357 | → | 0.0% | 0.0% |
| 2024.03 | 2023/05/12 | 当初予 | 0 | - | - | - | -1,353 | - | - | - | -1,353 | - | - | - | -1,357 | - | - | - |
| 2023.03 | 2023/05/12 | 実 | 5 | → | 0.0% | 0.0% | -1,467 | ↑ | +10.3% | +10.3% | -1,473 | ↑ | +9.9% | +9.9% | -1,485 | ↑ | +9.3% | +9.3% |
| 2023.03 | 2023/02/10 | Q3予 | 5 | → | 0.0% | 0.0% | -1,635 | → | 0.0% | 0.0% | -1,635 | → | 0.0% | 0.0% | -1,637 | → | 0.0% | 0.0% |
| 2023.03 | 2022/11/11 | Q2予 | 5 | → | 0.0% | 0.0% | -1,635 | → | 0.0% | 0.0% | -1,635 | → | 0.0% | 0.0% | -1,637 | → | 0.0% | 0.0% |
| 2023.03 | 2022/08/12 | Q1予 | 5 | → | 0.0% | 0.0% | -1,635 | → | 0.0% | 0.0% | -1,635 | → | 0.0% | 0.0% | -1,637 | → | 0.0% | 0.0% |
| 2023.03 | 2022/05/12 | 当初予 | 5 | - | - | - | -1,635 | - | - | - | -1,635 | - | - | - | -1,637 | - | - | - |
| 2022.03 | 2022/05/12 | 実 | 15 | ↓ | -11.8% | +650.0% | -1,476 | ↑ | +20.3% | +20.3% | -1,481 | ↑ | +20.0% | +20.0% | -1,484 | ↑ | +20.0% | +20.0% |
| 2022.03 | 2022/03/30 | 修正予 | 17 | ↑ | +750.0% | +750.0% | - | - | - | - | -1,852 | → | 0.0% | 0.0% | -1,854 | → | 0.0% | 0.0% |
| 2022.03 | 2022/02/10 | Q3予 | 2 | → | 0.0% | 0.0% | -1,852 | → | 0.0% | 0.0% | -1,852 | → | 0.0% | 0.0% | -1,854 | → | 0.0% | 0.0% |
| 2022.03 | 2021/11/12 | Q2予 | 2 | → | 0.0% | 0.0% | -1,852 | → | 0.0% | 0.0% | -1,852 | → | 0.0% | 0.0% | -1,854 | → | 0.0% | 0.0% |
| 2022.03 | 2021/08/13 | Q1予 | 2 | → | 0.0% | 0.0% | -1,852 | → | 0.0% | 0.0% | -1,852 | → | 0.0% | 0.0% | -1,854 | → | 0.0% | 0.0% |
| 2022.03 | 2021/05/13 | 当初予 | 2 | - | - | - | -1,852 | - | - | - | -1,852 | - | - | - | -1,854 | - | - | - |
| 2021.03 | 2021/05/13 | 実 | 2 | ↓ | -33.3% | -33.3% | -1,732 | ↑ | +8.6% | +8.6% | -1,738 | ↑ | +8.2% | +8.2% | -1,719 | ↑ | +9.9% | +9.9% |
| 2021.03 | 2021/02/12 | Q3予 | 3 | → | 0.0% | 0.0% | -1,894 | → | 0.0% | 0.0% | -1,894 | → | 0.0% | 0.0% | -1,907 | → | 0.0% | 0.0% |
| 2021.03 | 2020/11/13 | Q2予 | 3 | → | 0.0% | 0.0% | -1,894 | → | 0.0% | 0.0% | -1,894 | → | 0.0% | 0.0% | -1,907 | → | 0.0% | 0.0% |
| 2021.03 | 2020/08/14 | Q1予 | 3 | → | 0.0% | 0.0% | -1,894 | → | 0.0% | 0.0% | -1,894 | → | 0.0% | 0.0% | -1,907 | → | 0.0% | 0.0% |
| 2021.03 | 2020/05/15 | 当初予 | 3 | - | - | - | -1,894 | - | - | - | -1,894 | - | - | - | -1,907 | - | - | - |
| 2020.03 | 2020/05/15 | 実 | 11 | → | 0.0% | +175.0% | -1,827 | ↑ | +24.4% | +24.4% | -1,823 | ↑ | +24.6% | +24.6% | -1,857 | ↑ | +23.8% | +23.8% |
| 2020.03 | 2020/02/14 | Q3予 | 11 | → | 0.0% | +175.0% | -2,417 | → | 0.0% | 0.0% | -2,417 | → | 0.0% | 0.0% | -2,437 | → | 0.0% | 0.0% |
| 2020.03 | 2020/01/17 | 修正予 | 11 | ↑ | +175.0% | +175.0% | -2,417 | → | 0.0% | 0.0% | -2,417 | → | 0.0% | 0.0% | -2,437 | → | 0.0% | 0.0% |
| 2020.03 | 2019/11/08 | Q2予 | 4 | → | 0.0% | 0.0% | -2,417 | → | 0.0% | 0.0% | -2,417 | → | 0.0% | 0.0% | -2,437 | → | 0.0% | 0.0% |
| 2020.03 | 2019/08/09 | Q1予 | 4 | → | 0.0% | 0.0% | -2,417 | → | 0.0% | 0.0% | -2,417 | → | 0.0% | 0.0% | -2,437 | → | 0.0% | 0.0% |
| 2020.03 | 2019/05/10 | 当初予 | 4 | - | - | - | -2,417 | - | - | - | -2,417 | - | - | - | -2,437 | - | - | - |
| 2019.03 | 2019/05/10 | 実 | 155 | ↑ | +3.3% | +3.3% | -1,665 | ↑ | +24.3% | +24.3% | -1,678 | ↑ | +23.7% | +23.7% | -1,884 | ↑ | +14.4% | +14.4% |
| 2019.03 | 2019/03/15 | 修正予 | 150 | → | 0.0% | 0.0% | -2,200 | → | 0.0% | 0.0% | -2,200 | → | 0.0% | 0.0% | -2,200 | → | 0.0% | 0.0% |
| 2019.03 | 2019/02/14 | Q3予 | 150 | → | 0.0% | 0.0% | -2,200 | → | 0.0% | 0.0% | -2,200 | → | 0.0% | 0.0% | -2,200 | → | 0.0% | 0.0% |
| 2019.03 | 2018/11/09 | Q2予 | 150 | → | 0.0% | 0.0% | -2,200 | → | 0.0% | 0.0% | -2,200 | → | 0.0% | 0.0% | -2,200 | → | 0.0% | 0.0% |
| 2019.03 | 2018/08/10 | Q1予 | 150 | → | 0.0% | 0.0% | -2,200 | - | - | - | -2,200 | → | 0.0% | 0.0% | -2,200 | → | 0.0% | 0.0% |
| 2019.03 | 2018/05/11 | 当初予 | 150 | - | - | - | - | - | - | - | -2,200 | - | - | - | -2,200 | - | - | - |
| 2018.03 | 2018/05/11 | 実 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2018.03 | 2018/02/14 | Q3予 | 280 | → | 0.0% | 0.0% | -2,000 | → | 0.0% | 0.0% | -2,000 | ↑ | +90.0% | 0.0% | -2,000 | → | 0.0% | 0.0% |
| 2018.03 | 2017/11/10 | Q2予 | 280 | → | 0.0% | 0.0% | -2,000 | → | 0.0% | 0.0% | -20,000 | ↓ | -900.0% | -900.0% | -2,000 | → | 0.0% | 0.0% |
| 2018.03 | 2017/08/14 | Q1予 | 280 | → | 0.0% | 0.0% | -2,000 | → | 0.0% | 0.0% | -2,000 | → | 0.0% | 0.0% | -2,000 | → | 0.0% | 0.0% |
| 2018.03 | 2017/05/12 | FY予 | 280 | - | - | - | -2,000 | - | - | - | -2,000 | - | - | - | -2,000 | - | - | - |
| 2017.12 | 2017/02/10 | 当初予 | 406 | - | - | - | -1,306 | - | - | - | -1,306 | - | - | - | -1,308 | - | - | - |
| 2017.03 | 2017/05/12 | 実 | 529 | ↑ | +30.3% | +30.3% | -1,113 | ↑ | +14.8% | +14.8% | -1,116 | ↑ | +14.5% | +14.5% | -1,113 | ↑ | +14.9% | +14.9% |
| 2017.03 | 2017/02/10 | 実 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2017.03 | 2016/11/11 | Q2予 | 406 | → | 0.0% | 0.0% | -1,306 | → | 0.0% | 0.0% | -1,306 | → | 0.0% | 0.0% | -1,308 | → | 0.0% | 0.0% |
| 2017.03 | 2016/08/15 | Q1予 | 406 | → | 0.0% | 0.0% | -1,306 | → | 0.0% | 0.0% | -1,306 | → | 0.0% | 0.0% | -1,308 | → | 0.0% | 0.0% |
| 2017.03 | 2016/05/13 | 当初予 | 406 | - | - | - | -1,306 | - | - | - | -1,306 | - | - | - | -1,308 | - | - | - |
| 2016.03 | 2016/05/13 | 実 | 822 | ↓ | -1.2% | -1.2% | -988 | ↑ | +26.3% | +26.3% | -992 | ↑ | +25.3% | +25.3% | -994 | ↑ | +25.2% | +25.2% |
| 2016.03 | 2016/02/12 | Q3予 | 832 | → | 0.0% | 0.0% | -1,341 | → | 0.0% | 0.0% | -1,328 | → | 0.0% | 0.0% | -1,329 | → | 0.0% | 0.0% |
| 2016.03 | 2015/11/13 | 当初予 | 832 | - | - | - | -1,341 | - | - | - | -1,328 | - | - | - | -1,329 | - | - | - |
